Please assess the completion status of the following clinical trial:

Trial Title: Study of Pemetrexed for Second-Line Pancreas Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the pancreas~* Prior treatment for distant or locally advanced disease with gemcitabine-based therapy~* Measurable or evaluable disease~* ECOG performance status 0-2~* Adequate hematological parameters~* Adequate baseline liver function~* At least 28 days from any major surgery~* At least 2 weeks from the last radiation treatment~* Must have recovered from reversible toxicities of prior chemotherapy~* Must be able to discontinue any nonsteroidal anti-inflammatory medications~* Must be willing to receive intramuscular vitamin B12 shots and take oral folate supplements~Exclusion Criteria:~* Any prior treatment with pemetrexed~* More than one prior chemotherapy regimen~* HIV positive on antiretroviral therapy~* Pregnant or lactating~* Prior organ allograft~* On concurrent antitumor therapy including radiation therapy or other chemotherapies~* Creatinine clearance 45 ml/min or less~* Absolute neutrophil count \< 1500~* Platelets \< 75,000~* Bilirubin \> 1.5 times the upper limit of normal~* Transaminases \> 3 times the upper limit of normal except in known liver metastasis wherein they may be \</= 5 times upper limit of normal~* Clinically significant ascites or pleural effusion that cannot be drained~* Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: EXPERIMENTAL): pemetrexed

Based on this trial design, predict the completion outcome and termination type (if applicable).